190 related articles for article (PubMed ID: 32586689)
1. Programmed death ligand 1 protein expression, histological tumour differentiation and intratumoural heterogeneity in pulmonary adenocarcinoma.
Tancoš V; Grendár M; Farkašová A; Huťka Z; Mičák J; Kviatkovská Z; Hardman TC; Hardy GAD; Plank L
Pathology; 2020 Aug; 52(5):538-545. PubMed ID: 32586689
[TBL] [Abstract][Full Text] [Related]
2. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
[No Abstract] [Full Text] [Related]
3. Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression.
Cai Y; Wu H; Shi X; Dong Y; Chang X; Zhang L; Zhou L; Su D; Yang M
BMC Cancer; 2020 Feb; 20(1):148. PubMed ID: 32093629
[TBL] [Abstract][Full Text] [Related]
4. Programmed Death-Ligand 1 Expression in Non-Small Cell Lung Carcinoma Biopsies and Its Association with Tumor Infi ltrat ing Lymphocytes and the Degree of Desmoplasia.
Tancoš V; Grendár M; Farkašová A; Huťka Z; Kviatkovská Z; Plank L
Klin Onkol; 2020; 33(1):55-65. PubMed ID: 32075390
[TBL] [Abstract][Full Text] [Related]
5. The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?
Bulutay P; Firat P; Zeren EH; Erus S; Tanju S; Dilege MŞ
Turk J Med Sci; 2021 Feb; 51(1):204-213. PubMed ID: 33155793
[TBL] [Abstract][Full Text] [Related]
6. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
7. Solid histological component of adenocarcinoma might play an important role in PD-L1 expression of lung adenocarcinoma.
Miyazawa T; Morikawa K; Otsubo K; Sakai H; Kimura H; Chosokabe M; Furuya N; Marushima H; Kojima K; Mineshita M; Koike J; Saji H
Thorac Cancer; 2022 Jan; 13(1):24-30. PubMed ID: 34811933
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotype.
Naso JR; Wang G; Pender A; Wong SK; Zhu J; Ho C; Ionescu DN; Zhou C
Histopathology; 2020 Feb; 76(3):394-403. PubMed ID: 31454429
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
[TBL] [Abstract][Full Text] [Related]
10. [Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].
Ma H; Jia J; Guo H; Zhao H; Wang C; Zhao L; Sun Y; Li W; Zhang Z
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):150-155. PubMed ID: 32209183
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas.
Zito Marino F; Rossi G; Montella M; Botti G; De Cecio R; Morabito A; La Manna C; Ronchi A; Micheli M; Salatiello G; Micheli P; Rocco D; Accardo M; Franco R
Am J Surg Pathol; 2020 Mar; 44(3):378-386. PubMed ID: 31688140
[TBL] [Abstract][Full Text] [Related]
12. Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma.
Serra P; Petat A; Maury JM; Thivolet-Bejui F; Chalabreysse L; Barritault M; Ebran N; Milano G; Girard N; Brevet M
Lung Cancer; 2018 Apr; 118():62-68. PubMed ID: 29572005
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
14. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
15. Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
Yanagawa N; Shiono S; Endo M; Ogata SY; Yamada N; Sugimoto R; Osakabe M; Uesugi N; Sugai T
Hum Pathol; 2021 Feb; 108():12-21. PubMed ID: 33159965
[TBL] [Abstract][Full Text] [Related]
16. Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas.
Ng Kee Kwong F; Laggner U; McKinney O; Croud J; Rice A; Nicholson AG
Histopathology; 2018 May; 72(6):1024-1032. PubMed ID: 29323731
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of resected pathological stage I lung adenocarcinoma: evaluating subtypes and PD-L1/CD155 expression.
Nishizawa N; Shimajiri S; Oyama R; Manabe T; Nemoto Y; Matsumiya H; Honda Y; Taira A; Takenaka M; Kuroda K; Tanaka F
Sci Rep; 2023 Dec; 13(1):21687. PubMed ID: 38065981
[TBL] [Abstract][Full Text] [Related]
18. Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas.
Yoon J; Suh YJ; Han K; Cho H; Lee HJ; Hur J; Choi BW
Thorac Cancer; 2020 Apr; 11(4):993-1004. PubMed ID: 32043309
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
Yoneshima Y; Ijichi K; Anai S; Ota K; Otsubo K; Iwama E; Tanaka K; Oda Y; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Apr; 118():36-40. PubMed ID: 29572000
[TBL] [Abstract][Full Text] [Related]
20. Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas.
Suda K; Shimoji M; Shimizu S; Sato K; Chiba M; Tomizawa K; Takemoto T; Soh J; Mitsudomi T
Biomolecules; 2019 Sep; 9(9):. PubMed ID: 31500267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
